Organogenesis Holdings Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Unaudited results; amounts below are USD millions unless stated otherwise. Organogenesis develops and sells regenerative medicine products in Advanced Wound Care and Surgical & Sports Medicine; it reports one operating segment. The filing was signed August 9, 2023.
Financial performance
| Metric | Q2 2023 | Q2 2022 | H1 2023 | H1 2022 |
|---|---|---|---|---|
| Net revenue | $117.3 | $121.4 | $225.0 | $218.5 |
| Gross profit | $91.0 | $94.7 | $172.0 | $166.8 |
| Gross margin | 77.6% | 78.1% | 76.5% | 76.3% |
| Operating income | $9.7 | $11.9 | $5.7 | $11.8 |
| Net income | $5.3 | $8.7 | $2.3 | $7.8 |
| Diluted EPS | $0.04 | $0.07 | $0.02 | $0.06 |
| Adjusted EBITDA | $15.4 | $18.6 | $19.2 | $23.6 |
Q2 revenue fell 3% year over year, mainly from lower Advanced Wound Care sales attributed to customer buying patterns; Surgical & Sports Medicine revenue declined 5%, with sales-force attrition and lower prices cited. H1 revenue rose 3% as Advanced Wound Care growth more than offset the Surgical & Sports Medicine decline. H1 gross profit increased 3%, helped by sales volume and a shift toward higher-margin products, but operating expenses rose 7% and operating income fell 51%. Net income declined 70% in H1.
H1 SG&A increased 6% to $144.2 million, reflecting travel and marketing, the timing of the annual sales meeting, legal and consulting expenses, ERP implementation costs, and restructuring; lower sales commissions partly offset these increases. R&D rose 18% to $22.1 million, reflecting pipeline product costs, clinical studies and staffing.
Cash flow, balance sheet and debt
- H1 operating cash flow was $3.6 million, down from $11.6 million. Investing cash outflow was $15.1 million, all capital expenditures, versus $12.8 million. Financing cash outflow was $2.3 million. Cash, cash equivalents and restricted cash decreased $13.8 million to $89.5 million.
- At June 30, cash and cash equivalents were $88.9 million; working capital was $143.0 million. Accounts receivable was $93.6 million and inventory $25.4 million.
- Term-loan principal was $69.4 million, with no revolver borrowings and $125.0 million available. The loan is secured by substantially all assets, including intellectual property; quarterly financial covenants were met. The agreement matures August 2026, with a $50.6 million remaining principal balance due at maturity. Operating lease liabilities totaled $53.1 million.
- Stockholders’ equity was $271.3 million; accumulated deficit was $43.6 million. H1 capital expenditures exceeded operating cash flow, contributing to the cash decline.
Outlook, risks and notable items
- Management expects cash, working capital, revolver availability and product-sale cash flows to fund operating costs, capital expenditures and debt service for at least 12 months beyond the filing date. The filing provides no numerical full-year revenue or earnings guidance.
- Three Medicare Administrative Contractors published final coverage determinations on August 3, 2023, effective September 17. Apligraf and Dermagraft remained covered, while PuraPly, Novachor, TransCyte, Affinity and NuShield were designated non-covered for DFUs and VLUs in the applicable Medicare jurisdictions. The company disputes the exclusions and warns that they could materially reduce utilization and revenue; the outcome of its engagement with the relevant parties was uncertain.
- Dermagraft manufacturing was suspended in Q4 2021 and sales in Q2 2022. The company plans to move production or use a third-party manufacturer and expects customers to substitute Apligraf, but cautions that failure to achieve savings or substitution could hurt results.
- A February 2023 workforce restructuring reduced headcount by 71, approximately 7%; the company reported $1.6 million of related charges in H1 and said the plan was substantially completed by March 31.
- Management reported disclosure controls and internal control over financial reporting were ineffective at June 30 because of a continuing material weakness involving significant non-routine transactions, IT general controls and segregation of duties. ERP implementation was delayed, with go-live anticipated in 2024.
- A securities class action alleging misleading statements concerning revenue, sales growth and certain products was pending; the company’s motion to dismiss was awaiting a court decision. Management said it intended to contest the claims.
- The filing says COVID-19 had not materially adversely affected results through June 30, but future effects remain uncertain. It also identifies economic and banking-system disruption as risks.
Investor verification priorities
- Track the effective date, geographic scope and any revisions or challenges to the Medicare coverage determinations, and assess their potential impact on affected-product revenue.
- Monitor quarterly revenue by product category, customer buying patterns, pricing and sales-force capacity, particularly in Surgical & Sports Medicine.
- Compare operating cash flow with capital expenditures and working-capital movements; verify continued access to the revolver and compliance with debt covenants.
- Check progress on Dermagraft manufacturing plans and the ERP implementation, including whether the material weakness is remediated and controls are tested as effective.
- Follow developments in the securities litigation and any material change in the company’s assessment of contingencies.